Please Wait.....
Report
Global Irritable Bowel Syndrome Treatment Market Report and Forecast 2023-2031
Market Report I 2023-04-22 I 160 Pages I EMR Inc.
Global Irritable Bowel Syndrome Treatment Market Report and Forecast 2023-2031
Global Irritable Bowel Syndrome Treatment Market Outlook
The global irritable bowel syndrome treatment market size attained a value of about USD 2.39 billion in 2022. The market is anticipated to grow at a CAGR of 10.13% during the forecast period of 2023-2031. The global irritable bowel syndrome treatment market share is anticipated to achieve a value of USD 5.71 billion by 2031.
Irritable Bowel Syndrome Epidemiology
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that affects the large intestine. The prevalence of IBS varies across different regions of the world, with an estimated global prevalence of around 10-15% of the population.
IBS can occur at any age, but it is most commonly diagnosed in people under the age of 50. It affects both men and women equally, although women tend to be diagnosed more frequently than men.
The prevalence of IBS varies widely across different regions of the world, with higher rates in developed countries. The condition is estimated to affect around 10-15% of the population globally, with higher rates in North America and Europe. In contrast, the prevalence is lower in Asia and Africa.
There are several lifestyle factors that can increase the risk of developing IBS, including stress, a sedentary lifestyle, and a diet high in processed foods and low in fibre. Other risk factors include a family history of the condition and a history of gastrointestinal infections.
In terms of prognosis, IBS is a chronic condition that can have a significant impact on quality of life. The symptoms of IBS, which include abdominal pain, bloating, and changes in bowel habits, can be managed with appropriate treatment. However, there is currently no cure for the condition.
In conclusion, IBS is a common gastrointestinal disorder that affects around 10-15% of the population globally. The condition is more prevalent in developed countries and is more commonly diagnosed in women than men. Lifestyle factors such as stress, a sedentary lifestyle, and a poor diet can increase the risk of developing IBS. While there is currently no cure for the condition, appropriate treatment can help manage symptoms and improve quality of life for affected individuals.
Global Irritable Bowel Syndrome Treatment Market Segmentations
Market Breakup by Type
- IBS-C
- IBS-C Market
- Linzess/Constella
- Amitiza
- Others
- IBS-D
- Xifaxan
- Viberz
- Others
Market Breakup by Application
- Cardiology
- Urology and Nephrology
- Oncology
- Gastroenterology
- Others
Market Breakup by End User
- Hospitals
- Clinics and Research Laboratories
- Others
Irritable Bowel Syndrome Treatment Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Global Irritable Bowel Syndrome Treatment Market Scenario
The global market for irritable bowel syndrome (IBS) treatment is expected to grow significantly in the coming years, driven by factors such as the increasing prevalence of the condition, a growing demand for effective treatment options, and the development of new and innovative therapies.
Antispasmodics are the most commonly used drugs for the treatment of IBS and are expected to continue to dominate the market during the forecast period. However, other drug classes such as antidepressants and laxatives are also expected to gain traction due to their efficacy in managing the symptoms of IBS.
Geographically, the market is expected to experience significant growth in North America and Europe due to the high prevalence of IBS in these regions and the presence of well-established healthcare infrastructure. However, the Asia Pacific region is expected to witness the highest growth rate due to the increasing prevalence of the condition and a growing demand for effective treatment options.
In conclusion, the global market for IBS treatment is expected to witness significant growth in the coming years due to the increasing prevalence of the condition and the development of new and innovative treatment options. The market is expected to be driven by factors such as the growing demand for effective treatments, the expanding product portfolios of key players in the market, and the increasing awareness about the condition among healthcare professionals and patients.
Key Players in the Global Irritable Bowel Syndrome Treatment Market
The report gives an in-depth analysis of the key players involved in the global irritable bowel syndrome market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Takeda Pharmaceutical Company Limited
- Astellas Pharma
- Ironwood Pharmaceuticals, Inc.
- AstraZeneca
- Sebela Pharmaceuticals Inc.
- Bausch Health
- Salix Pharmaceuticals
- Abbott Laboratories.
- Johnson & Johnson Services Inc.
- GlaxoSmithKline plc
- Ono Pharmaceutical Co., Ltd.
- Pfizer Inc.
- LEXICON PHARMACEUTICALS, INC
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Irritable Bowel Syndrome Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Irritable Bowel Syndrome Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Irritable Bowel Syndrome Epidemiology (2016-2031)
5.3 Europe Irritable Bowel Syndrome Epidemiology (2016-2031)
5.4 Asia-Pacific Irritable Bowel Syndrome Epidemiology (2016-2031)
5.5 Latin America Irritable Bowel Syndrome Epidemiology (2016-2031)
5.6 Middle East & Africa Irritable Bowel Syndrome Epidemiology (2016-2031)
6 Global Irritable Bowel Syndrome Treatment Market Overview
6.1 Global Irritable Bowel Syndrome Treatment Market Historical Value (2016-2022)
6.2 Global Irritable Bowel Syndrome Treatment Market Forecast Value (2023-2031)
7 Global Irritable Bowel Syndrome Treatment Market Landscape
7.1 Irritable Bowel Syndrome Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Irritable Bowel Syndrome Treatment: Product Landscape
7.2.1 Analysis by Product
7.2.2 Analysis by End User
8 Irritable Bowel Syndrome Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Irritable Bowel Syndrome Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter's Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Irritable Bowel Syndrome Treatment Market Segmentation
11.1 Global Irritable Bowel Syndrome Treatment Market by Type
11.1.1 Market Overview
11.1.2 IBS-C
11.1.2.1 IBS-C Market
11.1.2.2 Linzess/Constella
11.1.2.3 Amitiza
11.1.2.4 Others
11.1.3 IBS-D
11.1.3.1 Xifaxan
11.1.3.2 Viberz
11.1.3.3 Others
11.2 Global Irritable Bowel Syndrome Treatment Market by Application
11.2.1 Market Overview
11.2.2 Cardiology
11.2.3 Urology and Nephrology
11.2.4 Oncology
11.2.5 Gastroenterology
11.2.6 Others
11.3 Global Irritable Bowel Syndrome Treatment Market by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Clinics and Research Laboratories
11.3.4 Others
11.4 Global Irritable Bowel Syndrome Treatment Market by Region
11.4.1 Market Overview
11.4.2 North America
11.4.3 Europe
11.4.4 Asia Pacific
11.4.5 Latin America
11.4.6 Middle East and Africa
12 North America Irritable Bowel Syndrome Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Irritable Bowel Syndrome Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Irritable Bowel Syndrome Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Irritable Bowel Syndrome Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Irritable Bowel Syndrome Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Takeda Pharmaceutical Company Limited
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Astellas Pharma
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Ironwood Pharmaceuticals, Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 AstraZeneca
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Sebela Pharmaceuticals Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Bausch Health
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Salix Pharmaceuticals
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Abbott Laboratories.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Johnson & Johnson Services Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 GlaxoSmithKline plc
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Ono Pharmaceutical Co., Ltd.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Pfizer Inc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 LEXICON PHARMACEUTICALS, INC
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
24 Irritable Bowel Syndrome Treatment - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security